{"entity":{"id":"nct04977024","kind":"trial","name":"SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer","aka":[],"tldr":"A phase 2 trial of COVID-19 Vaccine in non-Hodgkin lymphoma and multiple myeloma, run by GeoVax, Inc., active and no longer recruiting.","summary":"SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer is a phase 2 interventional study registered as NCT04977024 by GeoVax, Inc., with 63 participants enrolled, started 2021-09-27 and due to reach its primary completion in 2026-12-31. Interventions recorded: COVID-19 Vaccine and Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04977024","url":"https://clinicaltrials.gov/study/NCT04977024"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma","multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04977024","phase":"2","setting":"A Phase 2 Randomized, Multi-center Study of GEO-CMO4S1 (SARS-CoV-2 Vaccine) Versus mRNA SARS-CoV-2 Vaccine in Patients Post Cellular Therapy for Hematological Malignancies","sponsor":"GeoVax, Inc.","enrolled":63,"outcomes":[]},"route":"/trials/nct04977024/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}]}}